Since President Trump was sworn into office for a second term, he has proposed or initiated changes impacting Medicare.

President Trump’s administration has made the decision not to cover highly-popular obesity treatments under the 2026 Medicare Advantage and Part D policies. One day after the Senate confirmed Dr ...

Benefits consultant Mercer has said that 44% of U.S. companies with 500 or more employees covered obesity drugs last year. Medicare does pay for drugs like Wegovy for patients who have heart ...

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...

The obesity drugs cost Medicare and Medicaid hundreds of dollars per patient each month, though the exact prices are secret. Many employers and private health insurance plans do not cover the drugs.

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government’s Medicare program.

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

The Biden administration proposal on obesity drugs. In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in ...